logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Sirna Therapeutics, Inc.


USPTO Granted Patents = 140

% Expired Patents = 13.6



Forward Citations = 2,242

Loading Chart...
Loading Chart...

118 inventors (with patents filed for the assignee):

goldMedal Leonid Beigelman (51 out of 227 patents)

silverMedal James A McSwiggen (37 out of 99 patents)

bronzeMedal Matthew G Stanton (32 out of 70 patents)

4.  Chandra Vargeese (25 out of 61 patents)

5.  Weimin Wang (21 out of 27 patents)

6.  Steven L Colletti (18 out of 40 patents)

7.  Duncan F Brown (15 out of 33 patents)

8.  Aarron T Willingham (11 out of 11 patents)

9.  Brian W Budzik (10 out of 12 patents)

10.  Vasant R Jadhav (10 out of 47 patents)

11.  Denise M Kenski (10 out of 12 patents)

12.  David M Tellers (9 out of 23 patents)

13.  Walter R Strapps (9 out of 21 patents)

14.  Lu Tian (9 out of 9 patents)

15.  James J Cunningham (9 out of 10 patents)


Core Competencies:
RNA Interference
Short Interfering Nucleic Acids
Oligonucleotide Delivery
Cationic Lipids
Chemical Modifications
Gene Expression Inhibition
Peptide Conjugates
Biodegradable Lipids
Micro RNA Mimetics
Myostatin
Hepatitis B Virus
CTNNB1

140 patents:

1. 12516321 - RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) (2026-01-06),
2. 12486503 - SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS (2025-12-02),
3. 12304925 - Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides (2025-05-20),
4. 11952573 - RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) (2024-04-09),
5. 11932854 - RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) (2024-03-19),
6. 11911475 - Low molecular weight cationic lipids for oligonucleotide delivery (2024-02-27),
7. 11530407 - Short interfering nucleic acid (siNA) compositions (2022-12-20),
8. 11413348 - Low molecular weight cationic lipids for oligonucleotide delivery (2022-08-16),
9. 11193126 - RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) (2021-12-07),
10. 11117917 - Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides (2021-09-14),
11. 10889815 - RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) (2021-01-12),
12. 10793860 - RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (SINA) (2020-10-06),
13. 10738308 - Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage (3dT) (2020-08-11),
14. 10729787 - Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety (2020-08-04),
15. 10689648 - Short interfering nucleic acid (siNA) compositions (2020-06-23),
Company Overview
Sirna Therapeutics, Inc., based in Cambridge, MA, specializes in the development of innovative therapies utilizing RNA interference technology. The company focuses on harnessing short interfering nucleic acids to inhibit gene expression, employing advanced methods for oligonucleotide delivery. Their research encompasses the use of cationic lipids, chemical modifications, and peptide conjugates to enhance therapeutic efficacy. Sirna Therapeutics is dedicated to advancing the field of gene silencing, aiming to provide novel solutions for various diseases through its cutting-edge scientific approaches.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

140 Patents

#18 in Cambridge, MA

#149 in Massachusetts

#2,785 in US

#5,786 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Sirna Therapeutics, Inc.

Forward Citations = 2,242

118 inventors:

goldMedal Leonid Beigelman (51 out of 227 patents)

silverMedal James A McSwiggen (37 out of 99 patents)

bronzeMedal Matthew G Stanton (32 out of 70 patents)

4.  Chandra Vargeese (25 out of 61 patents)

5.  Weimin Wang (21 out of 27 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sirna Therapeutics, Inc.. Retrieved from https://idiyas.com/company/sirna-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…